Aktienanalyse zu Vertex Pharmaceuticals Inc (VRTX)VRTXVertex Pharmaceuticals Inc

Vertex Pharmaceuticals Incorporated is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases. The Company has approved therapies for cystic fibrosis, sickle cell disease, transfusion-dependent beta thalassemia, acute pain and acromegaly, and it continues to advance clinical and research programs in these areas. It also has a clinical pipeline of investigational therapies across a range of modalities in other serious diseases where it has deep insight into causal human biology, including IgA nephropathy, neuropathic pain, APOL1-mediated kidney disease, primary membranous nephropathy, congenital adrenal hyperplasia, ACTH-dependent Cushing's syndrome, autosomal dominant polycystic kidney disease, type 1 diabetes, generalized myasthenia gravis, and myotonic dystrophy type 1. The Company's pipeline also includes PALSONIFY (paltusotine) and atumelnant. PALSONIFY is the once-daily oral therapy for acromegaly. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Vertex Pharmaceuticals is a good buy right now due to its current price of $523.93, which is below the average analyst price target of $619.75, indicating a potential upside of 18.2%. Additionally, the company's gross margin stands at a strong 85.33%, demonstrating its efficiency in generating profit from sales. The main risk to consider is the insider selling trend, which has increased by 753.33% over the last month, indicating potential concerns among company insiders.

27 analysts cover VRTX: 22 rate it Buy, 5 Hold and 0 Sell. The average price target is 515.88.